ATYR · XBRL financial data

aTYR PHARMA financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ATYR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	10,455	0	10,386	353	235	190
Research and development	17,291	23,264	42,808	42,293	54,372	60,219
General and administrative	9,075	10,751	13,982	12,979	13,777	17,598
Total operating expenses	26,366	34,015	56,790	55,272	68,149	77,817
Operating income (loss)	(15,911)	(34,015)	(46,404)	(54,919)	(67,914)	(77,627)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(16,224)	(33,768)	(45,338)	(50,389)	(64,023)	(74,118)
Earnings per share, basic USD per share	(1.77)	(1.77)	(1.60)	(0.94)	(0.86)	(0.80)
Earnings per share, diluted USD per share	(1.77)	(1.77)	(1.60)	(0.94)	(0.86)	(0.80)
Weighted average shares, basic thousands of shares	9,160	19,081	28,420	53,606	74,261	92,985
Weighted average shares, diluted thousands of shares	9,160	19,081	28,420	53,606	74,261	92,985

Fiscal years (ATYR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	16,952	2,336	9,981	22,544	11,055	10,743
Marketable securities	14,737	105,575	56,165	75,622	61,070	67,944
Total current assets	35,531	113,569	80,871	102,992	81,954	80,237
Property and equipment, net	899	543	3,059	5,531	4,850	4,263
Right-of-use asset	2,083	1,267	7,250	6,727	5,817	5,524
Total assets	38,726	115,537	95,786	120,653	96,830	93,003
Accounts payable	1,431	1,031	3,106	3,529	4,323	3,891
Accrued liabilities	3,572	4,002	9,862	11,559	9,392	9,791
Total current liabilities	5,864	6,013	13,862	16,416	14,967	15,148
Lease liability, non-current	1,378	398	9,633	12,339	11,144	10,308
Accumulated deficit	(338,528)	(372,296)	(417,634)	(468,023)	(532,046)	(606,164)
Total stockholders' equity	31,650	109,301	71,464	90,658	70,019	67,480
Total liabilities and equity	38,726	115,537	95,786	120,653	96,830	93,003
Common shares outstanding (cover page) thousands of shares	16,011	27,796	53,162	67,750	88,859	98,051

Fiscal years (ATYR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(16,224)	(33,768)	(45,338)	(50,389)	(64,023)	(74,118)
Depreciation and amortization	569	475	232	592	708	664
Net cash from operating activities	(15,301)	(33,075)	(41,886)	(33,221)	(69,119)	(61,986)
Purchases of property and equipment	202	192	1,641	4,215	65	77
Net cash from investing activities	6,900	(91,566)	47,245	(20,127)	17,233	(5,053)
Net cash from financing activities	16,143	110,025	5,451	66,230	39,864	66,011
Net change in cash	7,742	(14,616)	10,810	12,882	(12,022)	(1,028)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
aTYR PHARMA	16,160	not reported	(9,351)*	98.1M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Arvinas	88,000	500	(10,400)*	65.5M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
Arbutus Biopharma	19,171	1,014	(6,018)*	197.8M	15.4 quarters	Q2 FY26 10-QJun 30, 2026
Zevra Therapeutics	122,148	37,756	10,047*	59.5M	—	Q3 FY26 10-QSep 30, 2026
Theravance Biopharma	219,766	20,731	(6,965)*	51.9M	55.7 quarters	Q2 FY26 10-QJun 30, 2026
Myriad Genetics	115,200	190,700	(8,300)*	95.6M	13.9 quarters	Q2 FY26 10-QJun 30, 2026
Kura Oncology	70,242	20,874	(62,549)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
KalVista Pharmaceuticals	213,768	40,863	(14,455)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
CytoDyn	16,359	not reported	(7,726)	1.5B	2.1 quarters	Q1 FY27 10-QAug 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.